Thursday, September 07, 2017 4:07:52 PM
To be an accredited investor, a person must demonstrate an annual income of $200,000, or $300,000 for joint income, for the last two years with expectation of earning the same or higher income. An individual must have earned income above the thresholds either alone or with a spouse over the last three years. The income test cannot be satisfied by showing one year of an individual's income and the next two years of joint income with a spouse. The exception to this rule is when a person is married within the period of conducting a test. A person is also considered an accredited investor if he has a net worth exceeding $1 million, either individually or jointly with his spouse. The SEC also considers a person to be an accredited investor if he is a general partner, executive officer, director or a related combination thereof for the issuer of unregistered securities.
http://www.investopedia.com/terms/a/accreditedinvestor.asp#ixzz4s1cP0okV
The reason why the above is important is because you have to be an
accredited investor to invest in ALLM's 506 (c) offering. As you
can see from above, you have to make good money to be an accredited
investor. And in this world, you have to be pretty smart to make
good money. And too bad for ALLM that dealing with smart people
doesn't bode well for them because smart people can see right throug
their BS!
<<What is a 506(c) offering?
506(c) allows companies to offer and sell securities to institutional or accredited investors. In comparison to traditional registered offerings, a 506(c) offering allows companies in earlier stages of development to raise money more cost-effectively.>>
https://www.transfer.ly/invest/alliance-bio-products
Recent BIOF News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 02:34:54 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 05:41:18 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 08/17/2023 01:26:03 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2023 05:43:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM